KR101789893B1 - 의학적 측정 곡선들을 평가하기 위한 방법 - Google Patents
의학적 측정 곡선들을 평가하기 위한 방법 Download PDFInfo
- Publication number
- KR101789893B1 KR101789893B1 KR1020157016553A KR20157016553A KR101789893B1 KR 101789893 B1 KR101789893 B1 KR 101789893B1 KR 1020157016553 A KR1020157016553 A KR 1020157016553A KR 20157016553 A KR20157016553 A KR 20157016553A KR 101789893 B1 KR101789893 B1 KR 101789893B1
- Authority
- KR
- South Korea
- Prior art keywords
- evaluation
- sample
- optical measurement
- measurement curve
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000005259 measurement Methods 0.000 title claims abstract description 577
- 238000000034 method Methods 0.000 title claims abstract description 343
- 238000011156 evaluation Methods 0.000 claims abstract description 341
- 230000003287 optical effect Effects 0.000 claims abstract description 325
- 210000001124 body fluid Anatomy 0.000 claims abstract description 187
- 239000012491 analyte Substances 0.000 claims abstract description 162
- 239000010839 body fluid Substances 0.000 claims abstract description 156
- 238000012360 testing method Methods 0.000 claims abstract description 156
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 154
- 238000001514 detection method Methods 0.000 claims abstract description 133
- 238000006243 chemical reaction Methods 0.000 claims abstract description 112
- 239000000126 substance Substances 0.000 claims abstract description 69
- 238000000491 multivariate analysis Methods 0.000 claims abstract description 49
- 230000004044 response Effects 0.000 claims abstract description 30
- 210000003743 erythrocyte Anatomy 0.000 claims description 82
- 238000004458 analytical method Methods 0.000 claims description 58
- 238000002848 electrochemical method Methods 0.000 claims description 38
- 238000012544 monitoring process Methods 0.000 claims description 36
- 230000006870 function Effects 0.000 claims description 35
- 238000010587 phase diagram Methods 0.000 claims description 34
- 238000003066 decision tree Methods 0.000 claims description 30
- 238000004590 computer program Methods 0.000 claims description 25
- 230000008859 change Effects 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 239000012530 fluid Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 238000011088 calibration curve Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 238000012628 principal component regression Methods 0.000 claims description 8
- 238000012706 support-vector machine Methods 0.000 claims description 7
- 210000003722 extracellular fluid Anatomy 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 238000010238 partial least squares regression Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 description 112
- 238000012937 correction Methods 0.000 description 42
- 230000033001 locomotion Effects 0.000 description 34
- 239000000306 component Substances 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
- 239000008103 glucose Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 230000001419 dependent effect Effects 0.000 description 15
- 238000004364 calculation method Methods 0.000 description 12
- DGPLSUKWXXSBCU-VGXGLJSLSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1r,2r,3s,4r)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)C2)O)=C1 DGPLSUKWXXSBCU-VGXGLJSLSA-N 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 9
- 150000008163 sugars Chemical class 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 7
- 238000010219 correlation analysis Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000013528 artificial neural network Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- -1 aromatic nitroso compounds Chemical class 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000000840 electrochemical analysis Methods 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012067 mathematical method Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011237 bivariate analysis Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
- G01N21/274—Calibration, base line adjustment, drift correction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/8483—Investigating reagent band
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/12—Circuits of general importance; Signal processing
- G01N2201/129—Using chemometrical methods
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Databases & Information Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Epidemiology (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Evolutionary Biology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Biophysics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mathematical Physics (AREA)
- Plasma & Fusion (AREA)
- Signal Processing (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198445.4 | 2012-12-20 | ||
| EP12198445 | 2012-12-20 | ||
| PCT/EP2013/077348 WO2014096174A1 (en) | 2012-12-20 | 2013-12-19 | Method for evaluating medical measurement curves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150090152A KR20150090152A (ko) | 2015-08-05 |
| KR101789893B1 true KR101789893B1 (ko) | 2017-11-20 |
Family
ID=47603061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157016553A Active KR101789893B1 (ko) | 2012-12-20 | 2013-12-19 | 의학적 측정 곡선들을 평가하기 위한 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150286778A1 (https=) |
| EP (1) | EP2936124B1 (https=) |
| JP (1) | JP6462585B2 (https=) |
| KR (1) | KR101789893B1 (https=) |
| CN (1) | CN104870982B (https=) |
| CA (1) | CA2896152C (https=) |
| HU (1) | HUE034313T2 (https=) |
| PL (1) | PL2936124T3 (https=) |
| WO (1) | WO2014096174A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2910360C (en) * | 2013-06-10 | 2018-07-10 | F. Hoffmann-La Roche Ag | Method and system for detecting an analyte in a body fluid |
| GB201507458D0 (en) * | 2015-04-30 | 2015-06-17 | Inside Biometrics Ltd | System and method for measuring fitness-related parameters |
| IT201600094056A1 (it) * | 2016-09-20 | 2018-03-20 | Bilimetrix S R L | Metodo di taratura per un dispositivo di misura della bilirubina |
| KR20200142541A (ko) * | 2018-04-06 | 2020-12-22 | 베링거잉겔하임베트메디카게엠베하 | 분석물의 측정 방법 및 분석 시스템 |
| EP3640946A1 (en) * | 2018-10-15 | 2020-04-22 | Sartorius Stedim Data Analytics AB | Multivariate approach for biological cell selection |
| PL3650843T3 (pl) * | 2018-11-07 | 2022-05-02 | F. Hoffmann-La Roche Ag | Sposoby i urządzenia do wykonywania pomiaru analitycznego |
| CN109682968B (zh) * | 2018-11-08 | 2022-03-11 | 上海艾瑞德生物科技有限公司 | 一种荧光免疫试条定量检测测试信号温度矫正方法 |
| JP2021092476A (ja) * | 2019-12-11 | 2021-06-17 | 清水建設株式会社 | 評価装置、評価方法、学習装置、及び学習方法 |
| JP2024507652A (ja) * | 2021-01-11 | 2024-02-21 | メソ スケール テクノロジーズ エルエルシー | アッセイシステムの較正システム及び方法 |
| US11796549B2 (en) * | 2021-02-12 | 2023-10-24 | Hach Company | Real-time management of analyte recovery |
| WO2022221884A1 (en) * | 2021-04-16 | 2022-10-20 | Beth Israel Deaconess Medical Center, Inc. | Systems and methods for non-selective stimulated echo multislice diffusion imaging |
| KR102717386B1 (ko) * | 2022-01-27 | 2024-10-15 | 스페클립스 주식회사 | 의료 진단 장치 및 이의 제어 방법 |
| WO2025162776A1 (en) | 2024-02-02 | 2025-08-07 | Roche Diabetes Care Gmbh | Analytical method for detecting at least one analyte in a bodily fluid |
| CN120257815B (zh) * | 2025-03-25 | 2026-03-31 | 南京埃德伯格智能技术有限公司 | 一种多目标优化下的废气净化方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005537891A (ja) | 2002-09-10 | 2005-12-15 | ユーロ−セルティーク エス．エイ． | 血液成分の非侵襲的測定のための装置及び方法 |
| WO2011131490A2 (en) | 2010-04-21 | 2011-10-27 | Siemens Healthcare Diagnostics Inc. | CURVE PROCESSOR ALGORITHM FOR THE QUALITY CONTROL OF (RT-)qPCR CURVES |
| JP5123314B2 (ja) | 2006-11-16 | 2013-01-23 | ゼネラル・エレクトリック・カンパニイ | 生体試料の連続分析 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3826922A1 (de) | 1988-08-09 | 1990-02-22 | Boehringer Mannheim Gmbh | Verfahren zur kolorimetrischen bestimmung eines analyten mittels enzymatischer oxidation |
| DE3940010A1 (de) | 1989-12-02 | 1991-06-06 | Boehringer Mannheim Gmbh | Verwendung eines schwer loeslichen salzes einer heteropolysaeure zur bestimmung eines analyts, entsprechendes bestimmungsverfahren sowie hierfuer geeignetes mittel |
| DE4221807C2 (de) * | 1992-07-03 | 1994-07-14 | Boehringer Mannheim Gmbh | Verfahren zur analytischen Bestimmung der Konzentration eines Bestandteiles einer medizinischen Probe |
| HU222809B1 (hu) | 1997-10-03 | 2003-10-28 | 77 Elektronika Műszeripari Kft. | Eljárás és készülék kémiai összetevőnek anyagmintából, különösen vér glükóztartalmának vérmintából történő meghatározásához |
| US20030036202A1 (en) * | 2001-08-01 | 2003-02-20 | Maria Teodorcyzk | Methods and devices for use in analyte concentration determination assays |
| US7118916B2 (en) * | 2002-10-21 | 2006-10-10 | Lifescan, Inc. | Method of reducing analysis time of endpoint-type reaction profiles |
| JP4745959B2 (ja) * | 2003-05-12 | 2011-08-10 | リバー・ダイアグノスティクス・ビー．・ブイ． | 微生物の自動特徴づけおよび分類 |
| JP5065013B2 (ja) * | 2004-05-14 | 2012-10-31 | バイエル・ヘルスケア・エルエルシー | グルコースアッセイにおいてヘマトクリットの調整を行う方法、およびそのための装置 |
| ES2315950T3 (es) | 2005-03-15 | 2009-04-01 | F. Hoffmann-La Roche Ag | Metodo y sistema para el analisis del metabolismo de la glucosa. |
| US20060281187A1 (en) * | 2005-06-13 | 2006-12-14 | Rosedale Medical, Inc. | Analyte detection devices and methods with hematocrit/volume correction and feedback control |
| DE102005035461A1 (de) | 2005-07-28 | 2007-02-15 | Roche Diagnostics Gmbh | Stabile NAD/NADH-Derivate |
| CN101915736B (zh) * | 2005-10-28 | 2012-06-20 | 松下电器产业株式会社 | 测定仪器、测定装置和测定方法 |
| US20070235346A1 (en) * | 2006-04-11 | 2007-10-11 | Popovich Natasha D | System and methods for providing corrected analyte concentration measurements |
| EP1909206A1 (de) | 2006-09-11 | 2008-04-09 | Roche Diagnostics GmbH | Messbereichserweiterung chromatografischer Schnellteste |
| EP1985996A1 (de) | 2007-04-27 | 2008-10-29 | Roche Diagnostics GmbH | Analysesystem zur photometrischen Bestimmung eines Analyten in einer Körperflüssigkeit mit einem Analysegerät und einem Testträger zur Aufnahme in das Analysegerät |
| ES2681895T3 (es) | 2007-06-18 | 2018-09-17 | F. Hoffmann-La Roche Ag | Método y sistema de control de la glucosa para monitorizar la respuesta metabólica individual y para generar una respuesta nutricional |
| PL2040072T3 (pl) * | 2007-09-22 | 2013-06-28 | Hoffmann La Roche | System analityczny do określania koncentracji analitu w płynie ustrojowym |
| MX2010006392A (es) | 2007-12-10 | 2010-07-02 | Bayer Healthcare Llc | Compensacion basada en la pendiente. |
| EP2093284A1 (de) | 2008-02-19 | 2009-08-26 | F.Hoffmann-La Roche Ag | Stabilisierung von Dehydrogenasen mit stabilen Coenzymen |
| CN101622541A (zh) | 2008-10-24 | 2010-01-06 | 韩国帕克特生物科技有限公司 | 糖化血红蛋白定量检测系统及使用该系统检测糖化血红蛋白含量的方法 |
| CA2769154C (en) | 2009-07-27 | 2015-10-27 | F. Hoffmann-La Roche Ag | Method and substances for preparation of n-substituted pyridinium compounds |
| CN102471793B (zh) | 2009-07-27 | 2014-04-30 | 霍夫曼-拉罗奇有限公司 | Carba-nad的酶促合成 |
| CN102471272B (zh) | 2009-07-27 | 2014-09-10 | 霍夫曼-拉罗奇有限公司 | 制备n-取代吡啶鎓化合物的方法和物质 |
| JP5812701B2 (ja) * | 2010-06-23 | 2015-11-17 | アークレイ株式会社 | 血漿グルコース測定方法 |
| NZ609363A (en) * | 2010-10-18 | 2015-04-24 | Nestec Sa | Methods for determining anti-drug antibody isotypes |
| EP3901624B1 (en) | 2010-12-22 | 2024-01-31 | Roche Diabetes Care GmbH | Methods to compensate for sources of error during electrochemical testing |
| JP5801590B2 (ja) * | 2011-04-11 | 2015-10-28 | シスメックス株式会社 | 生体成分測定方法 |
-
2013
- 2013-12-19 HU HUE13811932A patent/HUE034313T2/en unknown
- 2013-12-19 EP EP13811932.6A patent/EP2936124B1/en active Active
- 2013-12-19 CN CN201380067159.9A patent/CN104870982B/zh active Active
- 2013-12-19 KR KR1020157016553A patent/KR101789893B1/ko active Active
- 2013-12-19 JP JP2015548568A patent/JP6462585B2/ja active Active
- 2013-12-19 WO PCT/EP2013/077348 patent/WO2014096174A1/en not_active Ceased
- 2013-12-19 CA CA2896152A patent/CA2896152C/en active Active
- 2013-12-19 PL PL13811932T patent/PL2936124T3/pl unknown
-
2015
- 2015-06-19 US US14/744,971 patent/US20150286778A1/en not_active Abandoned
-
2019
- 2019-07-03 US US16/502,363 patent/US10984892B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005537891A (ja) | 2002-09-10 | 2005-12-15 | ユーロ−セルティーク エス．エイ． | 血液成分の非侵襲的測定のための装置及び方法 |
| JP5123314B2 (ja) | 2006-11-16 | 2013-01-23 | ゼネラル・エレクトリック・カンパニイ | 生体試料の連続分析 |
| WO2011131490A2 (en) | 2010-04-21 | 2011-10-27 | Siemens Healthcare Diagnostics Inc. | CURVE PROCESSOR ALGORITHM FOR THE QUALITY CONTROL OF (RT-)qPCR CURVES |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2896152C (en) | 2018-07-24 |
| EP2936124A1 (en) | 2015-10-28 |
| US20150286778A1 (en) | 2015-10-08 |
| WO2014096174A1 (en) | 2014-06-26 |
| JP2016505840A (ja) | 2016-02-25 |
| EP2936124B1 (en) | 2017-03-15 |
| US10984892B2 (en) | 2021-04-20 |
| PL2936124T3 (pl) | 2017-08-31 |
| KR20150090152A (ko) | 2015-08-05 |
| CN104870982A (zh) | 2015-08-26 |
| CN104870982B (zh) | 2019-02-15 |
| CA2896152A1 (en) | 2014-06-26 |
| US20190325992A1 (en) | 2019-10-24 |
| HUE034313T2 (en) | 2018-02-28 |
| JP6462585B2 (ja) | 2019-01-30 |
| HK1213992A1 (zh) | 2016-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101789893B1 (ko) | 의학적 측정 곡선들을 평가하기 위한 방법 | |
| JP6441812B2 (ja) | 体液試料を分析する方法 | |
| US8744776B2 (en) | Method for determining analyte concentration based on complex index functions | |
| CN113490843B (zh) | 采用拉曼光谱确定病毒滴度的方法 | |
| US11644434B2 (en) | Biosensor system analyte measurement | |
| KR20230028556A (ko) | 라만 분광법을 사용하여 바이러스를 분석하는 방법 | |
| CA2843157A1 (en) | Extrapolation of interpolated sensor data to increase sample throughput | |
| Sulaiman et al. | Hybrid ensemble-based machine learning model for predicting phosphorus concentrations in hydroponic solution | |
| Imaizumi et al. | Assessing transfer entropy from biochemical data | |
| JP7038230B2 (ja) | 細胞数を推定する方法および細胞数を推定する装置 | |
| HK1213992B (zh) | 用於评估医学测量曲线的方法 | |
| TW202546842A (zh) | 檢測體液中的至少一種分析物之分析方法 | |
| Chen et al. | Glucose and Lactate Sensing Using Raman Spectroscopy Based Upon Iterative Pls Machine Learning | |
| HK1213637B (en) | Method for analyzing a sample of a body fluid | |
| Kalivas | MULTICOMPONENT ANALYSIS USING THE GENERALIZED STANDARD ADDITION METHOD. | |
| Rocha¹ et al. | Assessment of Performance and Uncertainty in Qualitative Analytical Chemistry: A Metrological Approach based on the Eurachem/CITAC Guide | |
| HK1109787A1 (en) | Analytical method and instrument |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20150619 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170519 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170817 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20171018 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20171018 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20210929 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230921 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |